S-5119-119
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Sponsored by Edward Markey (D-MA)
What it does
This bill would require the U.S. Postal Service to continue selling the Alzheimer's semipostal stamp for an additional six years beyond the date it would otherwise be discontinued. A semipostal stamp is sold at a price above its postage value, with the surplus transferred to the National Institutes of Health to fund Alzheimer's disease research. The bill would also clarify that the stamp is issued under this new statutory authority, allowing it to be sold alongside other semipostal stamps without running into limits on simultaneous offerings.
Who benefits
Alzheimer's patients and their families, who may benefit from research funded by stamp proceeds. NIH researchers working on Alzheimer's disease. Stamp collectors and members of the public who wish to contribute to Alzheimer's research through a postal purchase. Advocacy organizations focused on Alzheimer's disease. Postal Service retail operations, which continue offering a popular product.
Who is hurt
The U.S. Postal Service bears administrative costs of continuing the program, which are not reimbursed by the surplus proceeds. Other disease research causes that compete for semipostal stamp slots may be indirectly disadvantaged if the Alzheimer's stamp occupies a concurrent offering position. Taxpayers who fund USPS operations absorb any net administrative overhead not covered by stamp revenue.
Supporters argue
Supporters argue that the Alzheimer's semipostal stamp has been a proven, low-cost mechanism for directing public contributions to medical research since its launch in 2017, generating funds for a disease that affects an estimated 6.7 million Americans and costs the healthcare system over $300 billion annually. They contend that extending the stamp for six years maintains a popular, voluntary funding channel with no mandatory tax burden on the public, and that the bipartisan, bicameral sponsorship reflects broad consensus that Alzheimer's research remains critically underfunded relative to its societal impact.
Opponents argue
Opponents argue that semipostal stamps are an inefficient and inequitable funding mechanism — the surplus revenue generated is modest compared to direct NIH appropriations, and the administrative costs borne by the Postal Service reduce the net benefit to research. They contend that Congress should prioritize Alzheimer's research through the standard appropriations process, where funding levels can be set transparently and proportionally, rather than relying on a retail novelty that directs a small, unpredictable revenue stream to NIH outside of normal budget oversight.
Constitutional context
No significant constitutional issue is present. Congress has clear authority under the Postal Clause (Art. I, §8, cl. 7) and the Taxing and Spending Clause (Art. I, §8, cl. 1) to direct USPS operations and channel proceeds to federal agencies like NIH. This bill modifies an existing statutory program and does not raise Commerce Clause, coercion, or religious liberty questions addressed in NFIB v. Sebelius (2012) or Burwell v. Hobby Lobby (2014).
Checks and balances
Congress gains narrow directive authority over USPS stamp offerings; the Postal Service retains operational discretion over implementation, and NIH remains subject to existing appropriations oversight for how research funds are spent.
Historical precedent
The Breast Cancer Research semipostal stamp, first authorized in 1997 and repeatedly reauthorized, is the direct model for this program and has raised over $90 million for NIH breast cancer research through the same surplus-stamp mechanism.